Advancements of liver transplantation for hepatocellular carcinoma in Korea

Research output: Contribution to journalReview articleResearchpeer-review

6 Citations (Scopus)

Abstract

The Milan criteria are still considered the gold standard for patient selection criteria for liver transplantation in patients with hepatocellular carcinoma. However, those criteria may be too strict and thus exclude a significant number of patients who could benefit from liver transplantation. Based on this notion, many expanded selection criteria have been suggested. In Asian countries, where there is a serious shortage of deceased donor organs, living donor liver transplantation accounts for the majority of all liver transplant cases. Because living donor liver transplantation is not controlled by the public allocation system, the indications for living donor liver transplantation can be expanded. In Korea, living donor liver transplantation depends entirely on the discretion of the transplant team and the donor. Hence, Korean transplant centers have had a reasonable amount of experience with liver transplantation for advanced hepatocellular carcinoma. Experiences in Korea show that serum alpha-fetoprotein level, des-gamma-carboxy prothrombin level and positron emission tomography are very useful biomarkers in predicting tumor recurrence after transplantation. Tumors that show favorable levels of these biomarkers might not recur after transplantation despite being morphologically advanced. In addition, combination therapy with mammalian target of rapamycin inhibitors and sorafenib may improve survival even after tumor recurrence. Therefore, in Korea, living donor liver transplantation is considered even for cases of far advanced hepatocellular carcinoma if a recipient has no other effective treatment options and a well-informed donor wishes to willingly participate.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number2
DOIs
StatePublished - 1 Feb 2017

Fingerprint

Korea
Liver Transplantation
Hepatocellular Carcinoma
Living Donors
Patient Selection
Tissue Donors
Transplants
Transplantation
Biomarkers
Recurrence
Neoplasms
alpha-Fetoproteins
Sirolimus
Positron-Emission Tomography
Survival
Liver
Therapeutics
Serum

Keywords

  • Biomarker
  • Carcinoma
  • Expanded criteria
  • Hepatocellular
  • Liver
  • Selection criteria
  • Transplantation

Cite this

@article{15ed96d9b4994346bf444a78fa10241b,
title = "Advancements of liver transplantation for hepatocellular carcinoma in Korea",
abstract = "The Milan criteria are still considered the gold standard for patient selection criteria for liver transplantation in patients with hepatocellular carcinoma. However, those criteria may be too strict and thus exclude a significant number of patients who could benefit from liver transplantation. Based on this notion, many expanded selection criteria have been suggested. In Asian countries, where there is a serious shortage of deceased donor organs, living donor liver transplantation accounts for the majority of all liver transplant cases. Because living donor liver transplantation is not controlled by the public allocation system, the indications for living donor liver transplantation can be expanded. In Korea, living donor liver transplantation depends entirely on the discretion of the transplant team and the donor. Hence, Korean transplant centers have had a reasonable amount of experience with liver transplantation for advanced hepatocellular carcinoma. Experiences in Korea show that serum alpha-fetoprotein level, des-gamma-carboxy prothrombin level and positron emission tomography are very useful biomarkers in predicting tumor recurrence after transplantation. Tumors that show favorable levels of these biomarkers might not recur after transplantation despite being morphologically advanced. In addition, combination therapy with mammalian target of rapamycin inhibitors and sorafenib may improve survival even after tumor recurrence. Therefore, in Korea, living donor liver transplantation is considered even for cases of far advanced hepatocellular carcinoma if a recipient has no other effective treatment options and a well-informed donor wishes to willingly participate.",
keywords = "Biomarker, Carcinoma, Expanded criteria, Hepatocellular, Liver, Selection criteria, Transplantation",
author = "Lee, {Hae Won} and Kyungsuk Suh",
year = "2017",
month = "2",
day = "1",
doi = "10.1093/jjco/hyw168",
language = "English",
volume = "47",
pages = "93--100",
journal = "Japanese journal of clinical oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

Advancements of liver transplantation for hepatocellular carcinoma in Korea. / Lee, Hae Won; Suh, Kyungsuk.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 2, 01.02.2017, p. 93-100.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Advancements of liver transplantation for hepatocellular carcinoma in Korea

AU - Lee, Hae Won

AU - Suh, Kyungsuk

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The Milan criteria are still considered the gold standard for patient selection criteria for liver transplantation in patients with hepatocellular carcinoma. However, those criteria may be too strict and thus exclude a significant number of patients who could benefit from liver transplantation. Based on this notion, many expanded selection criteria have been suggested. In Asian countries, where there is a serious shortage of deceased donor organs, living donor liver transplantation accounts for the majority of all liver transplant cases. Because living donor liver transplantation is not controlled by the public allocation system, the indications for living donor liver transplantation can be expanded. In Korea, living donor liver transplantation depends entirely on the discretion of the transplant team and the donor. Hence, Korean transplant centers have had a reasonable amount of experience with liver transplantation for advanced hepatocellular carcinoma. Experiences in Korea show that serum alpha-fetoprotein level, des-gamma-carboxy prothrombin level and positron emission tomography are very useful biomarkers in predicting tumor recurrence after transplantation. Tumors that show favorable levels of these biomarkers might not recur after transplantation despite being morphologically advanced. In addition, combination therapy with mammalian target of rapamycin inhibitors and sorafenib may improve survival even after tumor recurrence. Therefore, in Korea, living donor liver transplantation is considered even for cases of far advanced hepatocellular carcinoma if a recipient has no other effective treatment options and a well-informed donor wishes to willingly participate.

AB - The Milan criteria are still considered the gold standard for patient selection criteria for liver transplantation in patients with hepatocellular carcinoma. However, those criteria may be too strict and thus exclude a significant number of patients who could benefit from liver transplantation. Based on this notion, many expanded selection criteria have been suggested. In Asian countries, where there is a serious shortage of deceased donor organs, living donor liver transplantation accounts for the majority of all liver transplant cases. Because living donor liver transplantation is not controlled by the public allocation system, the indications for living donor liver transplantation can be expanded. In Korea, living donor liver transplantation depends entirely on the discretion of the transplant team and the donor. Hence, Korean transplant centers have had a reasonable amount of experience with liver transplantation for advanced hepatocellular carcinoma. Experiences in Korea show that serum alpha-fetoprotein level, des-gamma-carboxy prothrombin level and positron emission tomography are very useful biomarkers in predicting tumor recurrence after transplantation. Tumors that show favorable levels of these biomarkers might not recur after transplantation despite being morphologically advanced. In addition, combination therapy with mammalian target of rapamycin inhibitors and sorafenib may improve survival even after tumor recurrence. Therefore, in Korea, living donor liver transplantation is considered even for cases of far advanced hepatocellular carcinoma if a recipient has no other effective treatment options and a well-informed donor wishes to willingly participate.

KW - Biomarker

KW - Carcinoma

KW - Expanded criteria

KW - Hepatocellular

KW - Liver

KW - Selection criteria

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85015757888&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyw168

DO - 10.1093/jjco/hyw168

M3 - Review article

VL - 47

SP - 93

EP - 100

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

SN - 0368-2811

IS - 2

ER -